A1, A2, B, C1, C2, D, E, F, G-H, I-K, L, M, N, O, P1, P2, Q-R, S, T, U-V, W-Z

Urispas Warnings, Precautions, Pregnancy, Nursing, Abuse - Flavoxate HCl

WARNINGS

Urispas (flavoxate HCl) should be given cautiously in patients with suspected glaucoma.

PRECAUTIONS

Information for Patients

See PATIENT INFORMATION section.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of Urispas (flavoxate HCl) have not been performed.

Pregnancy

Teratogenic Effects � Pregnancy Category B: Reproduction studies have been performed in rats and rabbits at doses up to 34 times the human dose and revealed no evidence of impaired fertility or harm to the fetus due to flavoxate HCl. There are, however, no well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Urispas is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in children below the age of 12 years have not been established.

top

Popular Searches:
weight loss	ultram	penis enlargement	hydrocodone	antibiotic